['ocular pain', 'dry eye syndrome']
['syl1001', 'syl1001', 'placebo']

        Inclusion Criteria:

          -  Give written informed consent to participate in the study, after having received all
             information relating to the design, aims and possible risks resulting therefrom.

          -  Common symptoms of persistent, daily, mild to moderate dry eye lasting more than three
             months: OSDI scale between 13-70 and VAS scale between 2 -7.

          -  Eye tests in both eyes: Corneal fluorescein staining (Oxford scale > 0), Tear break-up
             time < 10 seconds and Schirmer's test with anaesthesia < 10 mm/5min.

        Exclusion criteria:

          -  Women who are pregnant or breastfeeding or who have a positive urine pregnancy test.
             Women who do not commit to use a medically acceptable method of contraception from the
             time of selection and throughout the study.

          -  Any current, relevant disease, including respiratory disease, cardiovascular disease,
             endocrine disease, neurological disease, haematological disease, kidney disease,
             oncological disease, liver disease, gastrointestinal dysfunction, hypertension or
             active acute infectious processes.

          -  Previous chronic or recurrent processes which, according to the investigator, could
             affect the development of the study.

          -  Concomitant use of other medications with analgesic activity by any route of
             administration at the time of entry into the study.

          -  Change in any concomitant eye and/or systemic medication of the patient one month
             before the study and during the study.

          -  Changes in the pre-established administration schedule of artificial tears during the
             15 days before the study and during the 10 days of the study.

          -  Initiation of treatment with cyclosporine or changes in the dosage or administration
             schedule of cyclosporine within the 6 months before inclusion in the study.

          -  History of hypersensitivity to drugs.

          -  Use of contact lenses during the treatment and previous 15 days.

          -  History of drug abuse or drug or alcohol dependence.

          -  Laboratory abnormalities which, in the investigator's opinion, are clinically
             significant.

          -  Previous refractive surgery.

          -  Having participated in another clinical trial within the 2 months prior to inclusion.

          -  Another eye disease that is significant in the investigator's opinion.
      